onvansertib
Showing 1 - 9 of 9
Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation Trial (Onvansertib, FOLFIRI, Bevacizumab)
Not yet recruiting
- Metastatic Colorectal Cancer
- +2 more
- Onvansertib
- +3 more
- (no location specified)
Oct 24, 2023
Small-cell Lung Cancer, Small Cell Lung Carcinoma Trial in Pittsburgh (Onvansertib)
Recruiting
- Small-cell Lung Cancer
- Small Cell Lung Carcinoma
- Onvansertib
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Jul 29, 2022
Pancreatic Ductal Adenocarcinoma Trial in United States (Onvansertib, Nanoliposomal irinotecan, Leucovorin)
Recruiting
- Pancreatic Ductal Adenocarcinoma
- Onvansertib
- +3 more
-
Phoenix, Arizona
- +5 more
Dec 15, 2022
Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia Trial in Rochester (Biospecimen
Recruiting
- Recurrent Chronic Myelomonocytic Leukemia
- Refractory Chronic Myelomonocytic Leukemia
- Biospecimen Collection
- +3 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
Metastatic Colorectal Cancer, KRAS Gene Mutation Trial in United States (Onvansertib, Bevacizumab, FOLFIRI)
Active, not recruiting
- Metastatic Colorectal Cancer
- KRAS Gene Mutation
- Onvansertib
- +2 more
-
Phoenix, Arizona
- +6 more
Nov 10, 2022
Colorectal Cancer, Metastatic Colorectal Cancer Trial in United States (Onvansertib, FOLFIRI, Bevacizumab)
Recruiting
- Colorectal Cancer
- Metastatic Colorectal Cancer
- Onvansertib
- +2 more
-
Birmingham, Alabama
- +38 more
Jan 25, 2023
Metastatic Colorectal Cancer, KRAS Gene Mutation Trial (Onvansertib, Bevacizumab, FOLFIRI)
No longer available
- Metastatic Colorectal Cancer
- KRAS Gene Mutation
- Onvansertib
- +2 more
- (no location specified)
Jan 18, 2021
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal
Recruiting
- Borderline Resectable Pancreatic Adenocarcinoma
- +11 more
- Cobimetinib
- +3 more
-
Portland, OregonOHSU Knight Cancer Institute
Mar 22, 2022